Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Equity Average: 2011-2025

Historic Equity Average for Niagen Bioscience (NAGE) over the last 7 years, with Sep 2025 value amounting to $67.4 million.

  • Niagen Bioscience's Equity Average rose 107.22% to $67.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.4 million, marking a year-over-year increase of 107.22%. This contributed to the annual value of $37.3 million for FY2024, which is 30.50% up from last year.
  • Latest data reveals that Niagen Bioscience reported Equity Average of $67.4 million as of Q3 2025, which was up 12.82% from $59.8 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Equity Average ranged from a high of $67.4 million in Q3 2025 and a low of $20.9 million during Q3 2022.
  • In the last 3 years, Niagen Bioscience's Equity Average had a median value of $29.8 million in 2024 and averaged $38.2 million.
  • Its Equity Average has fluctuated over the past 5 years, first crashed by 46.13% in 2022, then soared by 107.22% in 2025.
  • Over the past 5 years, Niagen Bioscience's Equity Average (Quarterly) stood at $33.6 million in 2021, then decreased by 26.02% to $24.8 million in 2022, then increased by 12.21% to $27.9 million in 2023, then skyrocketed by 44.29% to $40.2 million in 2024, then surged by 107.22% to $67.4 million in 2025.
  • Its last three reported values are $67.4 million in Q3 2025, $59.8 million for Q2 2025, and $50.7 million during Q1 2025.